Session Type
Meeting
Search Results for adverse events
Abstract Number: 745
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Case Presentation: Case1: A 72- year old male with a diagnosis of stage four non-small cell Lung carcinoma who was treated with Pembrolizumab, presented two weeks after his first dose with generalized body aches and weakness. Labs showed elevated creatinine Kinase, increased serum creatinine with hyperkalemia to 5.6 and elevated troponins to as high as […]
Abstract Number: 786
SHM Converge 2023
Case Presentation: A 76-year-old female with a history of hypertension, BMI 48 kg/m2, hypothyroidism, and metastatic melanoma presented with a 2-week history of progressive myalgia, weakness, and dyspnea 3 weeks after the first infusion of nivolumab and relatlimab.In July 2019, she was diagnosed with stage IIB (cT4a, cN0, cM0) melanoma of the left leg (4.2 […]
Abstract Number: 837
SHM Converge 2023
Case Presentation: A 69-year-old male with a past medical history of urothelial carcinoma status post left nephrectomy began immunotherapy and was started on Atezolizumab. He developed bilateral lower extremity weakness that began following his first dose. After 3 doses, in 02/2022, his lower extremity weakness worsened to the point where he could not walk. A […]
Abstract Number: G23
SHM Converge 2022
Background: Communication related to medications is an important metric on the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey to measure patient experience after discharge from the hospital. There are many factors which can lead to poor communication about medications (Figure 1). Over 20% of readmissions can be related to medications, and of […]
Abstract Number: I11
SHM Converge 2022
Background: Opioid analgesia is an important treatment modality for patients with chronic pain, including pain attributed to cancer- and noncancer-related illness. Unfortunately, an estimated 40%–80% of opioid users experience opioid-induced constipation (OIC). Methylnaltrexone (MNTX) is indicated for the treatment of OIC. In clinical trials, the most common adverse events (AEs) were gastrointestinal (GI) in nature. […]
Abstract Number: 1105
Hospital Medicine 2020, Virtual Competition
Case Presentation: An elderly man was diagnosed with clear cell renal cell carcinoma in 1987, and treated with left nephrectomy, though developed multi-organ metastatic disease in 2015. After he did not tolerate initial treatment with sunitinib, he received 15 cycles of NKTR-214 and nivolumab as part of a phase I/II study. Three months after his […]